Sugi Predict

Sugi Predict / Compounds / Pyridine

Pyridine

Pyridine

SCHEMBL360206

O=C(Cl)C(=O)Cl.c1ccncc1

nearest known ligand 0.56

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NAPRT Q6XQN6 4/20 0.56
▸ TSHR P16473 1/20 0.56
▸ TDP1 Q9NUW8 1/20 0.56
▸ KMT2A Q03164 3/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ GAA P10253 2/20 0.37
▸ APP P05067 1/20 0.37
▸ HCAR3 P49019 1/20 0.37
▸ HCAR2 Q8TDS4 1/20 0.37
▸ PLOD2 O00469 2/20 0.34
▸ TAAR1 Q96RJ0 1/20 0.34
▸ PLOD3 O60568 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ PLOD1 Q02809 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridine SCHEMBL27310910 0.97 NAPRT (0.53) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL936385 0.90 NAPRT (0.60) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL6730524 0.90 NAPRT (0.60) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL9851406 0.90 NAPRT (0.60) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL29133271 0.88 NAPRT (0.56) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL4636073 0.87 — —
Pyridine SCHEMBL8916332 0.85 NAPRT (0.53) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL367908 0.85 NAPRT (0.53) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL910099 0.83 NAPRT (0.69) NAPRTTSHRTDP1KMT2AMEN1
Pyridine SCHEMBL5278800 0.83 NAPRT (0.69) NAPRTTSHRTDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040185029-A1 Polymeric drug TANG HAIZHONG (US) 2004-09-23 — — US claimed
EP-3800178-A1 PREPARATION OF ENAMIDE INTERMEDIATE FOR THE SYNTHESIS OF DASOTRALINE Moehs Ibérica, S.L. (ES) 2021-04-07 — — EP disclosed
US-10435351-B2 Enamide process SUNOVION PHARMACEUTICALS INC. (US) 2019-10-08 — — US disclosed
WO-2018144385-A1 ENAMIDE PROCESS SUNOVION PHARMACEUTICALS INC. (US) 2018-08-09 — — WO disclosed
US-20180215702-A1 ENAMIDE PROCESS SUNOVION PHARMACEUTICALS INC. 2018-08-02 — — US disclosed
US-10011559-B2 Preparation of chiral amides and amines SUNOVION PHARMACEUTICALS INC. (US) 2018-07-03 — — US disclosed
US-20180016224-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. 2018-01-18 — — US disclosed
EP-2816024-B1 Chiral amines SUNOVION PHARMACEUTICALS INC (US) 2017-08-02 — — EP disclosed
US-20160016891-A1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC. 2016-01-21 — — US disclosed
EP-2013835-B1 PREPARATION OF CHIRAL AMIDES AND AMINES SUNOVION PHARMACEUTICALS INC (US) 2015-11-04 — — EP disclosed
EP-2013835-A2 PREPARATION OF CHIRAL AMIDES AND AMINES Sepracor Inc. (US) 2009-01-14 — — EP disclosed
CN-101072758-A Quinazoline derivatives ASTRAZENECA AB (SE) 2007-11-14 — — CN disclosed
WO-2007115185-A2 PREPARATION OF CHIRAL AMIDES AND AMINES SEPRACOR INC. (US) 2007-10-11 — — WO disclosed
US-20040185029-A1 Polymeric drug TANG HAIZHONG (US) 2004-09-23 — — US disclosed
US-20040185029-A1 Polymeric drug TANG HAIZHONG (US) 2004-09-23 — — US disclosed
EP-1000041-A1 1,3-DIAZA- HETEROCYCLES AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 2000-05-17 — — EP disclosed
US-5958958-A ANTIINFLAMMATORY AGENT; HYPOTENSIVE AGENT G.D. SEARLE & CO. (US) 1999-09-28 — — US disclosed
US-5892050-A CONDENSATION OF ALKYL VINYL ETHER WITH VILSMEIER REAGENT AND OXALACETATE AND AMMONIA AMERICAN CYANAMID COMPANY (US) 1999-04-06 — — US disclosed
WO-1999005131-A1 1,3-DIAZA- HETEROCYCLES AND THEIR USE AS NITRIC OXIDE SYNTHASE INHIBITORS G.D. SEARLE & CO. (US) 1999-02-04 — — WO disclosed
EP-0004949-B1 4-AZA-17-SUBSTITUTED-5-ALPHA-ANDROSTAN-3-ONE, THEIR A AND D HOMO ANALOGS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM MERCK & CO. INC. (US) 1983-09-21 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10011559-B2 Preparation of chiral amides and amines PNMT, ALKBH5, ALKBH2 NAPRT 133/4885TSHR 888/4885TDP1 1320/4885
US-20180016224-A1 PREPARATION OF CHIRAL AMIDES AND AMINES PNMT, ALKBH2, ALKBH5 NAPRT 133/4885TSHR 1146/4885TDP1 1318/4885
US-20160016891-A1 PREPARATION OF CHIRAL AMIDES AND AMINES PNMT, ALKBH5, ALKBH2 NAPRT 133/4885TSHR 888/4885TDP1 1320/4885
US-20180215702-A1 ENAMIDE PROCESS ENO1, ENY2, ALKBH2 NAPRT 137/4885TSHR 1365/4885TDP1 2765/4885
US-10435351-B2 Enamide process ENO1, ENY2, ALKBH2 NAPRT 137/4885TSHR 1365/4885TDP1 2765/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.